Back

Effectiveness and safety of sacubitril/valsartan in patients with stage 4 chronic kidney disease in a real-world population

29 June 2021 (08:00 - 23:59)
Organised by:
Congress Presentation Part of: ePoster session Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Joana Brito

Santa Maria University Hospital CHLN Lisbon Academic Medical Centre, Lisbon (Portugal)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.
20 May 2023
thumbnail
Congress Presentation
REVEAL-CKD: Prevalence of undiagnosed stage 3 chronic kidney disease in patients with heart failure in Canada
20 May 2023
thumbnail
Congress Presentation
Chronic kidney disease impact after mitraclip therapy: five-year outcomes from the GRASP registry
1 July 2021
thumbnail
Congress Presentation
Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME
31 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources